fingolimod hydrochloride has been researched along with Psoriasis in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fabbrocini, G; Fornaro, L; Megna, M; Noto, M | 1 |
| Fujita, H; Ikumi, N | 1 |
| Asano, Y; Kamata, M; Mitsui, A; Okura, I; Sato, S; Shimizu, T; Tada, Y | 1 |
| Chen, X; Ji, M; Jin, J; Lai, F; Wang, Y; Xue, N; Zhang, S; Zhang, X | 1 |
| Bäumer, W; Dickhaut, J; Japtok, L; Kietzmann, M; Kleuser, B; Mischke, R; Schaper, K | 1 |
5 other study(ies) available for fingolimod hydrochloride and Psoriasis
| Article | Year |
|---|---|
A case of psoriasis and multiple sclerosis succesfully treated with concomitant fingolimod and secukinumab.
Topics: Antibodies, Monoclonal, Humanized; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Psoriasis; Severity of Illness Index; Treatment Outcome | 2023 |
Generalized pustular psoriasis occurring in a patient with multiple sclerosis during treatment with fingolimod.
Topics: Chronic Disease; Etretinate; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Psoriasis; Skin Diseases, Vesiculobullous | 2023 |
Fingolimod ameliorates imiquimod-induced psoriasiform dermatitis by sequestrating interleukin-17-producing ?d T cells in secondary lymph nodes.
Topics: Animals; Disease Models, Animal; Down-Regulation; Drug Evaluation, Preclinical; Female; Fingolimod Hydrochloride; Humans; Imiquimod; Interleukin-17; Intraepithelial Lymphocytes; Langerhans Cells; Lymph Nodes; Mice; Psoriasis; Skin; Up-Regulation | 2021 |
Validating a Selective S1P
Topics: Administration, Oral; Animals; Animals, Outbred Strains; Anti-Inflammatory Agents, Non-Steroidal; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Fingolimod Hydrochloride; Guinea Pigs; Mice; Mitotic Index; Mucous Membrane; Oxazoles; Propanolamines; Psoriasis; Random Allocation; Receptors, Lysosphingolipid; Reproducibility of Results; Skin; Specific Pathogen-Free Organisms; Sphingosine-1-Phosphate Receptors; Vagina | 2018 |
Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cell Differentiation; Cell Proliferation; Dermatologic Agents; Disease Models, Animal; Female; Fingolimod Hydrochloride; Humans; Imiquimod; Keratinocytes; Local Lymph Node Assay; Lysophospholipids; Mice; Mice, Inbred BALB C; Mice, SCID; Propylene Glycols; Psoriasis; Receptors, Lysosphingolipid; Skin; Skin Transplantation; Sphingosine; Sphingosine-1-Phosphate Receptors; Time Factors | 2013 |